{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "regularMarketChangePercent": 1.6983426, "regularMarketPrice": 25.15, "marketState": "PRE", "currency": "USD", "exchange": "NGM", "shortName": "Inhibrx, Inc.", "longName": "Inhibrx, Inc.", "messageBoardId": "finmb_563995161", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "fiftyDayAverageChangePercent": 0.17354463, "twoHundredDayAverage": 23.8012, "twoHundredDayAverageChange": 1.3487988, "twoHundredDayAverageChangePercent": 0.05666936, "marketCap": 1147056256, "forwardPE": -5.931604, "priceToBook": 72.478386, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2020-08-19", "averageAnalystRating": "1.8 - Buy", "tradeable": false, "cryptoTradeable": false, "firstTradeDateMilliseconds": 1597843800000, "priceHint": 2, "regularMarketChange": 0.42000008, "regularMarketTime": 1684180804, "regularMarketDayHigh": 26.21, "regularMarketDayRange": "24.27 - 26.21", "regularMarketDayLow": 24.27, "regularMarketVolume": 312095, "regularMarketPreviousClose": 24.73, "bid": 0.0, "ask": 0.0, "bidSize": 9, "askSize": 13, "fullExchangeName": "NasdaqGM", "financialCurrency": "USD", "regularMarketOpen": 24.96, "averageDailyVolume3Month": 427386, "averageDailyVolume10Day": 543890, "fiftyTwoWeekLowChange": 17.48, "fiftyTwoWeekLowChangePercent": 2.279009, "fiftyTwoWeekRange": "7.67 - 34.72", "fiftyTwoWeekHighChange": -9.570002, "fiftyTwoWeekHighChangePercent": -0.27563366, "fiftyTwoWeekLow": 7.67, "fiftyTwoWeekHigh": 34.72, "earningsTimestamp": 1683576302, "earningsTimestampStart": 1691405940, "earningsTimestampEnd": 1691755200, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": -3.46, "epsForward": -4.24, "epsCurrentYear": -4.15, "priceEpsCurrentYear": -6.0602407, "sharesOutstanding": 43615700, "bookValue": 0.347, "fiftyDayAverage": 21.4308, "fiftyDayAverageChange": 3.7192001, "displayName": "Inhibrx", "symbol": "INBX"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "11025 North Torrey Pines Road", "address2": "Suite 200 Torrey Pines Science Park", "city": "La Jolla", "state": "CA", "zip": "92037", "country": "United States", "phone": "858 795 4220", "website": "https://inhibrx.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Inhibrx, Inc., a clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has collaboration with 2seventy bio, Inc., Bristol-Myers Squibb Company, and Chiesi Farmaceutici S.p.A. The company was founded in 2010 and is headquartered in La Jolla, California.", "fullTimeEmployees": 132, "companyOfficers": [{"maxAge": 1, "name": "Mr. Mark Paul Lappe", "age": 55, "title": "Founder, Chairman, Pres & CEO", "yearBorn": 1967, "fiscalYear": 2022, "totalPay": {"raw": 1022750, "fmt": "1.02M", "longFmt": "1,022,750"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Brendan P. Eckelman Ph.D.", "age": 43, "title": "Founder & Chief Scientific Officer", "yearBorn": 1979, "fiscalYear": 2022, "totalPay": {"raw": 704000, "fmt": "704k", "longFmt": "704,000"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Kelly Devine Deck B.S., CPA, M.S.", "age": 41, "title": "Exec. VP & CFO", "yearBorn": 1981, "fiscalYear": 2022, "totalPay": {"raw": 531168, "fmt": "531.17k", "longFmt": "531,168"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 1445398, "fmt": "1.45M", "longFmt": "1,445,398"}}, {"maxAge": 1, "name": "Mr. Quinn L. Deveraux", "title": "Founder", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Ashraf  Amanullah", "age": 54, "title": "Exec. VP & Chief Technical Operations Officer", "yearBorn": 1968, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Leah  Pollema J.D.", "title": "VP, Corp. Sec. & Gen. Counsel", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Charbel  Helaihel Pharm.D.", "title": "VP of Marketing & Commercial Planning", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Jeffrey J. Jensen", "title": "Exec. VP & Chief Clinical Operations Officer", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. David  Matly M.B.A.", "title": "Exec. VP & Chief Commercial Officer", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Carlos  Bais Ph.D.", "title": "Exec. VP of Translational Sciences", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "auditRisk": 6, "boardRisk": 10, "compensationRisk": 7, "shareHolderRightsRisk": 8, "overallRisk": 9, "governanceEpochDate": 1682899200, "compensationAsOfEpochDate": 1672444800, "maxAge": 86400}}], "error": null}}